Nantahala Capital Management, LLC In8 Bio, Inc. Transaction History

Nantahala Capital Management, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$2.02 - $4.68 $411,983 - $954,495	-203,952 Reduced 57.82%	148,801 $359,000
Q1 2022 May 13, 2022	SELL	$2.76 - $4.6 $56,348 - $93,913	-20,416 Reduced 5.47%	352,753 $1.23 Million
Q4 2021 Feb 14, 2022	SELL	$4.39 - $8.55 $8,038 - $15,655	-1,831 Reduced 0.49%	373,169 $1.64 Million
Q3 2021 Nov 15, 2021	BUY	$6.71 - $10.0 $2.52 Million - $3.75 Million	375,000 New	375,000 $2.57 Million

7.62M

Ticker INAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,502,200
Market Cap $6.13M
Description
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of...

Get notified when there are updates to the investment portfolio of Nantahala Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Nantahala Capital Management, LLC with notifications on news.